Items where authors include "Besuyen, R"

Article

Mease, P, Coates, LC, Helliwell, PS et al. (14 more authors) (2018) Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. The Lancet, 392 (10162). pp. 2367-2377. ISSN 0140-6736

Conference or Workshop Item

Mease, PJ, Coates, LC, Van den Bosch, F et al. (8 more authors) (2021) Correlation Between Skin Involvement, Joint Involvement and Enthesitis in Patients with Active Psoriatic Arthritis: Post-hoc Analysis of EQUATOR/EQUATOR2. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Helliwell, P orcid.org/0000-0002-4155-9105, Coates, LC, Van den Bosch, F et al. (7 more authors) (2021) The Effect of Filgotinib on Enthesitis: 100-Week Data from an Open-Label Extension Study in Patients with Active Psoriatic Arthritis. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Coates, LC, Mease, PJ, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Effect of Filgotinib on Pasdas: Drivers of Low and Very Low Activity up to Week 100. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Coates, LC, Gladman, DD, Van den Bosch, F et al. (10 more authors) (2021) Long-Term Outcomes with Filgotinib, an Oral Preferential Janus Kinase 1 Inhibitor: 100-Week Data from an Open-Label Extension (OLE) Study in Patients with PSA. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Mease, P, Coates, L, Van den Bosch, F et al. (7 more authors) (2020) Effect of Filgotinib on the Complete Resolution of Enthesitis in Psoriatic Arthritis (PsA) Patients: 52-week Results from EQUATOR2. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Coates, L, Gladman, D, Van den Bosch, F et al. (10 more authors) (2020) Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA). In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2020) Long-Term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020.

Gladman, DD, Coates, LC, Van den Bosch, F et al. (9 more authors) (2020) FRI0339 LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2). In: EULAR 2020, 03-06 Jun 2020, Online.

Helliwell, P, Van den Bosch, F, Coates, LC et al. (9 more authors) (2020) FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR). In: EULAR 2020, 03-06 Jun 2020, Online.

Husni, ME, Gladman, DD, Helliwell, P et al. (9 more authors) (2020) FRI0344 THE LONG-TERM EFFECT OF TREATING PSORIATIC ARTHRITIS WITH THE JANUS KINASE 1-SELECTIVE INHIBITOR FILGOTINIB ON LIPID PROFILES: AN ANALYSIS OF THE EQUATOR AND EQUATOR2 TRIALS. In: EULAR 2020, 03-06 Jun 2020, Online.

Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2020) Long-term safety of filgotinib in patients with PsA: week 52 safety data from a Phase 2 open-label extension study. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020, Cancelled.

Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2019) Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study. In: 2019 ACR/ARP Annual Meeting Minutes, 08-13 Nov 2019, Atlanta, Georgia, USA.

Proceedings Paper

Mease, PJ, Gladman, DD, van den Bosch, F et al. (10 more authors) (2018) Filgotinib, an Oral, Selective Janus Kinase 1 Inhibitor, Is Effective in Psoriatic Arthritis Patients with an Inadequate Response to Conventional Disease-Modifying Anti-Rheumatic Drugs: Results from a Randomized, Placebo-Controlled, Phase 2 Study. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .